Trials / Unknown
UnknownNCT04977570
A Study of SYHA1805 in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Phase Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of SYHA1805 in Chinese Healthy Adult Subjects.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose of SYHA1805.
Detailed description
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics, multiple ascending doses of SYHA1805 tablets or matching placebo tablets will be randomly administered to 36 Chinese healthy subjects under fasting condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYHA1805 tablets | Oral tablets of SYHA1805 with three pre-designed doses |
| DRUG | Placebo | Oral tablets of placebo with matching doses |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2022-05-01
- Completion
- 2022-05-01
- First posted
- 2021-07-27
- Last updated
- 2021-07-27
Source: ClinicalTrials.gov record NCT04977570. Inclusion in this directory is not an endorsement.